<DOC>
	<DOCNO>NCT00974272</DOCNO>
	<brief_summary>The primary goal study determine acute effect exenatide postprandial hypertriglyceridemia . Secondary goal determine whether additional improvement postprandial lipid lipoproteins whether ( reduction hyperglycemia alone combination decline hyperlipidemia ) exenatide reduce pro-inflammatory potential postprandial period .</brief_summary>
	<brief_title>Effects Exenatide Postprandial Hyperlipidemia Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Recently diagnose type 2 diabetes ( within 3 year ) diet IGT Fasting triglyceride level &gt; 140 &lt; 400 mg/dl value vary less 35 % two screening measurement Normal liver function test white blood cell count Type 2 Diabetes &gt; 3 year HbA1c â‰¥ 7.5 Known suspect Type 1 Diabetes Any diabetes medication past 3 week , TZD prior 3 month prior regular use insulin Creatinine &gt; 2.0 mg/dl evidence active kidney disease Hepatic enzyme elevation &gt; 2x normal Known Nonalcoholic Fatty Liver Disease Malabsorption fat nutrient , severe lactose intolerance significant gastrointestinal pancreatic problem Recent history nausea vomit Acute bacterial viral illness evidence active infection past 4 week A prior cardiovascular event , stable unstable angina major illness past 6 month Current regular use antiinflammatory medication antioxidant , include counter medication high dose salicylate ( &gt; 1 g/day ) Any lipid lowering therapy prior 3 week statin medication . Subjects receive statin medication must stable dose least 2 month prior participation .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>